Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 gives a protected harbor to advance looking explanations made by us or for our sake. This official statement contains articulations which establish "forward-looking proclamations" inside the significance of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including yet not restricted to explanations in regards to the normal utilization of the returns from the contribution. Any explanation that isn't chronicled in nature is a forward-looking assertion and might be recognized by the utilization of words and expressions, for example, "expects," "expects," "accepts," "will," "will probably result," "will proceed," "plans to," "potential," "promising," and comparable articulations. These assertions depend on administration's present assumptions and convictions and are dependent upon various dangers, vulnerabilities and suspicions that could make genuine outcomes contrast physically from those depicted in the forward-looking assertions, including the danger factors portrayed under the heading "Hazard Factors" set out in the Company's reports recorded with the SEC occasionally. No forward-looking assertion can be ensured, and genuine outcomes may contrast really from those anticipated. Relmada embraces no commitment to freely refresh any forward-looking assertion, regardless of whether because of new data, future occasions, or something else. Perusers are advised that it is unimaginable to expect to foresee or recognize every one of the dangers, vulnerabilities and different variables that may influence future outcomes and that the dangers portrayed thus ought not be a finished rundown.

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

Relmada Therapeutics Corporate Logo (PRNewsFoto/Relmada Therapeutics, Inc.)


Relmada Therapeutics, Inc.

May 01, 2021, 08:30 ET


NEW YORK, May 1, 2021/PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology organization tending to sicknesses of the focal sensory system (CNS), today reported that clinical information identified with REL-1017, the organization's lead item up-and-comer, will be introduced in two banners at the American Psychiatric Association (APA) Annual Meeting 2021, which is being held for all intents and purposes between May 1 and May 3, 2021.

Subtleties of the banner introductions are underneath:

Date/Time: May 1, 2021, from 1:00 – 1:30 PM ET

Banner Number: 5181크레이지슬롯
Title: Rapid and Sustained Antidepressant Effects of REL-1017 (esmethadone) as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial

Date/Time: May 1, 2021, from 1:00 – 1:30 PM ET

Banner Number: 5198

Title: Effect of Percentage of Life-Years from the Start of Major Depressive Disorder on the Therapeutic Response of REL-1017

The on-request banners are accessible for review online for the term of the gathering by enrolled meeting participants.